Company announces second office in Mumbai
WILMINGTON, N.C., Dec. 12 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Philip Mathew, M.D., as director of strategic development, to lead the company's Phase II-IV operations and expansion in India.
Dr. Mathew will provide strategic leadership for PPD's drug development business on the Indian subcontinent, including clinical project management and patient recruitment for key therapeutic areas. He will also be responsible for identifying and helping to develop new clinical sites and business opportunities as well as liaising with local and national government departments.
"A native of India, Dr. Mathew brings extensive clinical trials experience and in-depth knowledge of the healthcare industry in this country," said Simon Britton, vice president of clinical operations for PPD in Asia. "His leadership will enable us to strengthen our presence in this important global clinical research market as we continue to meet the growing needs of our clients. We are pleased to welcome him to PPD."
The company also announced it is opening a second Mumbai office, where Dr. Mathew will be based. The office, located at the Dynasty facility in the Mumbai business district, expands the company's global footprint for providing clinical services.
Prior to joining PPD, Dr. Mathew was associate medical director at Covance Inc. He had previously served as principal investigator with MDS Pharma Services; attending physician with the Robert Wood Johnson University Hospital; instructor of medicine with the University of Medicine and Dentistry of New Jersey; staff physician with the Clinical Research Center of the Robert Wood Johnson Medical School and University of Medicine and Dentistry of New Jersey; and consultant physician with the Church of South India Mission Hospital.
Dr. Mathew attended St. Joseph's College at Calicut University in Kerala, India, and received bachelor's degrees in medicine and surgery from Calicut Medical College. He earned his medical degree in general medicine from Christian Medical College at Vellore in Tamil Nadu, India. Certified by the American Board of Internal Medicine and in its subspecialty of infectious diseases, Dr. Mathew has authored numerous publications and presentations.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations
and assumptions, including expectations and assumptions about the
above-named employee's performance and value to PPD contained in this news
release are forward-looking statements that involve a number of risks and
uncertainties. Although PPD attempts to be accurate in making those
forward-looking statements, it is possible that future circumstances might
differ from the assumptions on which such statements are based. In
addition, other important factors which could cause results to differ
materially include the following: the ability to attract and retain key
personnel; economic conditions and outsourcing trends in the
pharmaceutical, biotechnology and medical device industries and
government-sponsored research sector; loss of or delay in large contracts;
dependence on collaborative relationships; rapid technological advances
that make our products and services less competitive; risks associated with
acquisitions and investments, such as impairments; competition within the
outsourcing industry; continued success in sales growth; and the other risk
factors set forth from time to time in the SEC filings for PPD, copies of
which are available free of charge upon request from the PPD investor
Sue Ann Pentecost
+919 456 5690
+910 558 7585
|SOURCE PPD, Inc.|
Copyright©2007 PR Newswire.
All rights reserved